Alogliptin benzoate

CAS : 850649-62-6

Ref. 3D-FA61528

Informations sur le produit

• Nom: Alogliptin benzoate
• Synonymes: 2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzonitrile benzoate
• Marque: Biosynth
• Description: Alogliptin benzoate is an orally active DPP-IV inhibitor that is used for the treatment of type 2 diabetes. Alogliptin benzoate is a prodrug that is hydrolyzed to alogliptin in vivo, which binds to the DPP-IV enzyme and blocks it from degrading the incretin hormones, GLP-1 and GIP. These hormones are released by the ileum after a meal and act on pancreatic beta cells to release insulin. Alogliptin benzoate has been shown to improve glucose levels after a meal, while reducing postprandial glucagon levels, as well as improving insulin sensitivity in patients with type 2 diabetes mellitus. Alogliptin benzoate also reduces bowel disease symptoms such as abdominal pain, diarrhea, and constipation in patients with type 2 diabetes. The analytical method used for measuring alogliptin benzoate concentration in plasma or serum is chromatographic analysis with postpr

Propriétés chimiques

• Masse moléculaire: 461.51 g/mol
• Formule: C₁₈H₂₁N₅O₂C₇H₆O₂
• Degré de pureté: Min. 95%
• Couleur/Forme: White Powder